Results 31 to 40 of about 4,857 (187)
F1000Research, 2021 Drug abuse may damage basal ganglia that are essential for planning and execution of movements. We report about the case of a 38-year old patient with ischemic lesions of the basal ganglia presenting with bilateral painful dystonia and parkinsonism ...
Natalia Szejko +3 more
doaj +1 more source
Frontiers in Psychiatry, 2022 BackgroundThe prevalence of cannabis use and cannabis use disorders (CUD) has significantly increased over time. However, there are no approved pharmacological treatments for CUD.
Caroline Vuilleumier +5 more
doaj +1 more source
Molecules, 2020 Hemp (Cannabis sativa L.) is currently one of the most controversial and promising crops. This study compared nine wild hemp (C. sativa spp. spontanea V.) accessions with 13 registered cultivars, eight breeding lines, and one cannabidiol (CBD) hemp ...
Valtcho D. Zheljazkov +6 more
doaj +1 more source
Metabolites, 2021 Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines
Anne Scheunemann +7 more
doaj +1 more source
Frontiers in Psychiatry, 2020 Alzheimer’s Dementia (AD) is a devastating neurodegenerative disease that affects approximately 17% of people aged 75–84. Neuropsychiatric symptoms (NPS) such as delusions, agitation, anxiety, and hallucinations are present in up to 95% of patients in ...
Michaela Defrancesco, Alex Hofer
doaj +1 more source
A Scoping Systematic Review of Cannabis Use in Endometriosis
Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.ABSTRACT Background Endometriosis, affecting 6%–10% of reproductive‐age women, causes chronic pelvic pain, dysmenorrhea, and infertility. Current treatments have limitations and consequently there is rising interest in effects of cannabis on pain and inflammation associated with endometriosis.
Kindha McLaren +2 more
wiley +1 more source
Single oral administration of dronabinol increases ocular blood flow in patients with glaucoma
Acta Ophthalmologica, EarlyView.Abstract Purpose Glaucoma is a leading cause of irreversible blindness globally, primarily driven by elevated intraocular pressure (IOP). Still, some patients progress despite significant IOP lowering, potentially due to impaired ocular blood flow. This study aimed to evaluate the effects of dronabinol, a synthetic tetrahydrocannabinol derivative, on ...
Theresa Lindner +9 more
wiley +1 more source
Health Technology Assessment, 2015 Background: The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ9-tetrahydrocannabinol (Δ9-THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid ...
Susan Ball +11 more
doaj +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.Abstract There is a paucity of high‐quality evidence on the clinical efficacy of cannabis‐based medicinal products (CBMPs). The objective of this study was to perform trajectory k‐means clustering of health‐related quality of life (HRQoL) outcomes in patients prescribed CBMPs to identify distinct response patterns and baseline predictors of treatment ...
Simon Erridge +10 more
wiley +1 more source